Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
47.54
+0.38 (0.81%)
Dec 24, 2024, 4:00 PM EST - Market closed
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for HALO stock have an average target of 61.11, with a low estimate of 49 and a high estimate of 73. The average target predicts an increase of 28.54% from the current stock price of 47.54.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HALO stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 3 | 2 | 2 | 2 |
| Hold | 2 | 2 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $68 | Strong Buy | Reiterates | $68 | +43.04% | Dec 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $68 | Strong Buy | Reiterates | $68 | +43.04% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $68 | Strong Buy | Reiterates | $68 | +43.04% | Nov 20, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $51 → $52 | Hold | Maintains | $51 → $52 | +9.38% | Nov 4, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $72 → $73 | Buy | Maintains | $72 → $73 | +53.55% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
1.02B
from 829.25M
Increased by 23.36%
Revenue Next Year
1.18B
from 1.02B
Increased by 15.35%
EPS This Year
4.23
from 2.10
Increased by 101.38%
EPS Next Year
4.98
from 4.23
Increased by 17.70%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.3B | 1.6B | |||
| Avg | 1.0B | 1.2B | 1.4B | |||
| Low | 964.1M | 1.1B | 1.3B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 28.5% | 27.7% | 34.7% | |||
| Avg | 23.4% | 15.3% | 21.5% | |||
| Low | 16.3% | 7.8% | 12.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.41 | 5.67 | 7.83 | |||
| Avg | 4.23 | 4.98 | 6.45 | |||
| Low | 4.00 | 4.51 | 5.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 110.0% | 34.1% | 57.4% | |||
| Avg | 101.4% | 17.7% | 29.6% | |||
| Low | 90.4% | 6.6% | 14.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.